PRKG1 Antibodies

cGMP-dependent protein kinase 1 (PRKG1)

Serine/threonine protein kinase that acts as crucial mediator of the nitric oxide (NO)/cGMP signaling pathway. GMP binding activates PRKG1, which phosphorylates serines and threonines on many cellular proteins.

Numerous protein targets for PRKG1 phosphorylation are implicated in regulating cellular calcium, but the contribution of each of these targets may vary substantially among cell types. Proteins that are phosphorylated by PRKG1 modulate platelet activation and adhesion, smooth muscle contraction, cardiac function, gene expression, feedback of this NO-signaling pathway, and other processes involved in a number of facets of the CNS such as axon guidance, hippocampal and cerebellar learning, circadian rhythm and nociception.

Gene Information

Human
Gene Name:	PRKG1
Uniprot:	Q13976
Entrez:	5592

Family

Belongs to:
protein kinase superfamily

Alternative Names

AAT8; cGK 1; cGK; cGK1; cGKI; cGKI-alpha; cGKI-BETA; cGMP-dependent protein kinase I; DKFZp686K042; EC 2.7.11; EC 2.7.11.12; FLJ36117; PKG; PKG1; PRKG1B; PRKG1BMGC71944; PRKGR1A; PRKGR1B; PRKGR1BcGMP-dependent, regulatory, type I, beta; protein kinase cGMP-dependent 1; protein kinase, cGMP-dependent, type I

Molecular Weight

Mass (kDA):
76.364 kDA

Genomic Context

Human
Location:	10q11.23-q21.1
Sequence:	10; NC_000010.11 (50990888..52298350)

Tissue Specificity

Primarily expressed in lung and placenta.

Subcellular Localizations

Cytoplasm. Colocalized with TRPC7 in the plasma membrane.

Diseases

• Hypertensive Disease
• Nervousness
• Observation Of Neuromuscular Block
• Malignant Neoplasms
• Hypertrophy
• Cardiovascular Diseases
• Cardiac Hypertrophy
• Pain
• Hypoxia
• Neoplasms
• Pathologic Vasoconstriction
• Erectile Dysfunction

• Vascular Diseases
• Malnutrition
• Heart Failure
• Diabetes Mellitus
• Attention Deficit Hyperactivity Disorder
• Pulmonary Hypertension
• Disease Of Adrenal Medulla

Interacting Proteins

• BMPR2
• FAM124A
• LMO2
• PDE5A
• ZNF646

Pathways

• Secretion
• Vasodilation
• Localization
• Cell Proliferation
• Transport
• Pathogenesis
• Relaxation Of Vascular Smooth Muscle
• Reverse Transcription
• Cell Death
• Platelet Activation
• Neutrophil Activation
• Aging
• Regulation Of Gene Expression

• Platelet Aggregation
• Sensitization
• Chemotaxis
• Translation
• Cell Cycle
• Vasoconstriction
• Induction Of Apoptosis

PTMs

• Phosphorylation
• Dephosphorylation
• Cleavage
• Oxidation

• Nitration
• Geranylgeranylation
• Ubiquitination
• Myristoylation

Research Areas

• Protein Kinase

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/PRKG1

Best Uses Of The PRKG1 Marker From Boster Bio

Boster has the antibodies you need regardless of whether you're trying for the top primary antibodies or the most effective heterologous boosters for the PRKG1 gene. The research community has highly validated and cited their antibodies. Boster primary antibodies are approved for Western Blotting, Immunohistochemistry, and ELISA. Boster Bio also offers qPCR primers, secondary antibodies and other antibodies.

Boster's primary antibodies

The PRKG1 fusion proteins is one of the most abundant proteins found in E. coli. It is also used to determine the presence of PRKG1-expressing cells. PRKG1 antibodies are highly specific for this protein and recognize both the membrane-bound and soluble isoforms. This protein is a key component of cardiovascular functions, and plays a significant role in cell growth and proliferation regulation.

NVSI-06/07 is a heterologous booster

The primary goal of this study was to examine the immunegenicity of homologous and heterologous booster vaccinations. Safety profiles within 30 minutes and 7 days after vaccination were the second outcomes. The outcome of the exploratory study was the presence of immunity against Omicron and other VOCs. AESIs and adverse events were also evaluated. The safety profile was determined by the frequency of adverse reactions within 30 days after vaccination.

The immunogenicity of the heterologous NVSI-06-07 booster was comparable among younger and older subjects. It also had similar safety profiles to the homologous boost. It was also well tolerated. It will therefore remain an option for the treatment of patients with immunosuppression. More studies are required to determine its effectiveness. It is still early to decide if NVSI 06-07 is an option that is worth considering.

The safety profile of the heterologous BBIBP-CorV/NVSI-06-07 prime-boost vaccination scheme supports the use of this approach. Many countries have approved this vaccine conditionally or emergency. It is also used for the primary vaccination of large populations. Its low risk of side effects could allow the use of it as a booster shot in future.

While the safety profile for NVSI-06-07 is acceptable, further research is required to confirm its effectiveness. The study involved nearly 1800 patients and two doses of BBIBP-CorV. Ninety-nine percent of NVSI06-07 patients received a heterologous boost with NVSI06-07. Ninety-one patients received a homologous booster, compared to 89 percent of NVSI-06/07 group.

The safety profile of NVSI-0607 is identical to that of the homologous booster. The adverse events were uncommon and were usually grade 2 or 3. The most commonly reported symptoms were fever, headache, and pain at the injection site. Three patients suffered from grade 3 systemic fever. Homologous and heterologous boosters did not cause with any serious adverse reactions. The homologous booster requires a dose-dependent titer evaluation.

The traditional technology for producing vaccines used in the "NVSI06-07" vaccine by Sinopharm is used. However, the inactivated form of the coronavirus that was originally created isn't harmful. The drug actually produces immune cells and antibodies. Patients are given two doses of the drug every 21 days. The WHO approved this product, however, not the FDA. It is currently being used in China, South America, Central Asia, and the UAE.

qPCR primers

The most popular qPCR method for determining the presence of the PRKG1 gene marker is the use of RNA-based qPCR primers. The primers are designed to amplify specific lengths of the PRKG1 gene. The melting curve for qPCR is the length of the amplicon targeted by the qPCR. A mistake in the alignment between the target amplicon and the primer can result in an 10 degree Celsius drop in melting temperatures. It is crucial to use primers that have the correct sequence and length in order to accurately analyze amplicons.

It is also important to choose the correct QPCR primers. Single nucleotide polymorphisms may hinder the amplification process leading to an incorrect allelic copy number interpretation. This could cause a failure in qPCR analysis. There are fortunately, a variety of efficient methods to determine the PRKG1 marker. Here's a brief overview of the most popular qPCR primers.

We tested a combination of primer/probe sets as well as an experimental strain that was designed to measure the efficiency of qPCR. The results were the same in the 10 negative controls, which suggested that there wasn't any distinction between the primers. The melting curves for the primer/probe pair showed the same trend across all the matrixes. However, a more detailed analysis is required to determine the optimum PRKG1 QPCR primers.

The study is limited due to its small sample size. The study comprised 10 female AIS patients and five healthy controls. While the number of patients was small, the gene expression of the major genes was confirmed in 10 patients. Further research is needed to understand the mechanism behind PRKG1 within AIS. Its function must be further explored through in-vivo and in vitro studies.

Best uses for the PRKG1 Marker

The PRKG1 marker can be utilized in a variety of applications and provides important information. PRKG1 can also be referred to as cGK1 or PRKG1B. It is a member of the cGMP family, and plays a key role in the process of signaling by a second messenger. PRKG1 activity is responsible for promoting DNA synthesis and inhibits pathological-level death caused by nitric oxide in smooth muscle cells. PRKG1 has a molecular weight of 76 to 78 kmDa. It can be expressed as a multimer fusion protein, with a monomer 65 kDa.